Bristol Myers' Breyanzi sales surged 125% in Q2 to $344M, fueled by new approvals, strong demand and expanded market reach.

Quarterly revenue from Yescarta came in at $393 million, which was a 5% decline from the second quarter of last year, while Tecartus saw a 14% drop-off to $92 million. In both cases, Gilead explained ...

The FDA has accepted for priority review the sBLA for lisocabtagene maraleucel to treat relapsed/refractory MZL.

During a live event, Nathan Denlinger, DO, MS, discussed outcomes of the ZUMA-7 trial in diffuse large B-cell lymphoma.

During a live event, Matthew Lunning, DO, and participants discussed the process of determining if patients with DLBCL should ...

In August 2025, Hoffmann-La Roche announced a study is to compare the efficacy and safety of glofitamab in combination with ...

Bristol-Myers Squibb recently reported a strong earnings quarter. **The company raised its full-year revenue guidance by $700 million**. This update reflects robust sales growth from key therapies and ...

The FDA has granted priority review for the epcoritamab combination, with potential approval making it the first bispecific antibody regimen for second-line follicular lymphoma treatment. Epkinly ...

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...